CBLL

Analyst Note: CeriBell, Inc. (CBLL)

Date: 2026-06-20 Current Price: $18.03

1. Structural Readiness

Conservative Entry: — Breakout Level: — Extension: — ATR Current: 4.7% (High)

Setup Classification: FORMING

• Volatility Context: The current ATR of 4.7% places volatility in the "High" bucket (4–6%), which is the historical sweet spot for structural quality. This suggests the stock has sufficient momentum to move but requires a defined breakout to confirm the direction.

2. Thesis Layer

Thesis Status: TACTICAL / SETUP-LED There is no named secular thesis attached to this name as of 2026-06-20. This is not a macro-driven play (e.g., "aging population" or "AI in healthcare" as a primary driver). The conviction must be derived strictly from the quality of the technical setup (the forming coil) and the immediate business fundamentals reported in the most recent earnings cycle. We are judging this purely on the execution of the commercial ramp and the structural setup readiness, without inventing a broader narrative.

3. Business Fundamentals

Company Overview: CeriBell, Inc. is a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions in the acute care setting. The company operates a novel, point-of-care electroencephalography (EEG) platform known as the Ceribell System.

Business Model: The company generates revenue through two recurring sources:

• Sale of Wearables: Single-patient use devices.
• Subscription Fees: Monthly recurring revenue (MRR) charged to hospital customers for the use of the Clarity software, recorders, and the data portal.

Key Operational Metrics (as of Q1 2026 / FY 2025):

• Revenue Growth: The company reported $26.5 million in revenue for Q1 2026, representing a 29% year-over-year increase and 7% sequential growth. For the full year 2025, revenue reached $89.1 million, up 36% year-over-year from $65.4 million in 2024.
• Customer Base: As of Q1 2026, 680 hospitals were actively using the system, marking the strongest single quarter of account growth since becoming public with 33 net additions. As of December 31, 2025, adoption stood at over 600 hospitals.
• Product Pipeline & Regulatory:
• Delirium Solution: Received FDA 510(k) clearance in December 2025. Management expects a full commercial launch in Q4 2026 or Q1 2027.
• LVO Stroke Solution: Received FDA Breakthrough Device Designation in January 2026 for Large Vessel Occlusion (LVO) stroke detection.
• Reimbursement: In April 2026, the company received a supportive CMS proposed rule for a New Technology Add-on Payment (NTAP) for the delirium solution, proposing up to $2,171 in incremental reimbursement per patient.
• Financial Health: The company reported a gross margin of 88% in 2025. While net losses increased to $53.4 million in 2025 (vs. $40.5 million in 2024) due to infrastructure expansion, management stated in May 2026 that existing cash and equivalents are sufficient to fund operations and capital expenditures for at least the next 12 months.
• Market Opportunity: Management estimates the Total Addressable Market (TAM) in the U.S. at approximately $3.5 billion, nearly double the estimate from a year prior, driven by the expanded delirium indication.

4. Archetype and Conviction

Archetype: Growth Leader / Margin Inflector CeriBell fits the Growth Leader archetype, characterized by rapid revenue expansion (36% YoY in 2025, 29% YoY in Q1 2026) and high gross margins (88%). The company is transitioning from a pure R&D phase to a commercial scaling phase, evidenced by the 680-hospital footprint and the imminent full commercial launch of its delirium solution.

Conviction Stack:

• Thesis Strength: Low (Tactical only; no macro thesis).
• Evidence Quality: High. The evidence base is robust, citing specific earnings transcripts and SEC filings from May and February 2026. The data points to accelerating adoption (33 net additions in one quarter) and clear regulatory milestones (FDA clearance, CMS NTAP proposal).
• Structural Quality: Moderate to High. The ATR of 4.7% indicates healthy volatility. The setup is "Forming," meaning the structure is intact but the trigger is pending.
• Rerating Potential: High. The combination of a $3.5B TAM, 88% gross margins, and a clear path to full commercialization of the delirium solution (Q4 2026/Q1 2027) provides a strong fundamental backdrop for a multiple expansion *if* the technical breakout occurs.

5. Invalidations, Strengths, and Gaps

What Would Strengthen the Case:

• Technical: A daily close above the defined breakout level (resistance) with volume confirmation.
• Fundamental: Confirmation of the CMS NTAP rule finalization or accelerated hospital adoption rates exceeding the 33-per-quarter run rate.
• Product: Successful full commercial launch of the delirium solution in Q4 2026 as guided.

What Would Invalidate the Case:

• Fundamental: A significant slowdown in hospital additions or a delay in the delirium commercial launch beyond Q1 2027.
• Financial: A cash runway warning indicating funds are insufficient for the next 12 months (currently stated as sufficient).

Gaps in Evidence:

• Specific Guidance on Delirium Revenue: While the launch window is set (Q4 2026/Q1 2027), there is no specific revenue guidance attached to the delirium product launch in the provided evidence.
• LVO Timeline: The Breakthrough Designation is noted, but no specific commercial launch timeline or revenue contribution estimate is provided for the LVO solution.
• Profitability Path: While losses are expected to continue, there is no specific timeline provided for when the company expects to reach GAAP profitability, only that losses are expected in the "near term."

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key evidence: 1) 29% YoY revenue growth in Q1 2026 with 33 net hospital additions; 2) 88% gross margin and $3.5B TAM estimate; 3) FDA clearance for delirium solution and supportive CMS NTAP proposal; 4) Cash runway sufficient for 12+ months. Key risks: 1) Technical setup is "Forming" with no breakout fired yet; 2) Net losses increased to $53.4M in 2025; 3) Delirium commercial launch delayed beyond Q1 2027; 4) Reimbursement rates may be lower than the proposed $2,171. Sizing hint: Position size should reflect the "Forming" status; treat as a partial position until breakout confirmation. Expected path: Management expects full commercial launch of delirium solution in Q4 2026 or Q1 2027, which should drive further hospital adoption and revenue acceleration. Expected horizon: 6 to 12 months for the commercial ramp to materialize.